PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antiprotozoals, Agents against protozoal disease.
ATC vet code: QP51AX08
Pharmacodynamic properties
The active substance, Halofuginone, is an antiprotozoal agent of the quinazolinone derivate group (nitrogenous polyheterocycles). Halofuginone lactate is a salt whose antiprotozoal properties and activity against Cryptosporidium parvum have been demonstrated both in in vitro conditions and in artificial and natural infections. The compound has a cryptosporidiostatic effect on Cryptosporidium parvum. It is mainly active on the free stages of the parasite (sporozoite, merozoite). The concentrations to inhibit 50% and 90% of the parasites, in an in vitro test system, are IC50 < 0.1 μg/ml and IC90 of 4.5 μg/ml respectively.
Pharmacokinetic particulars
The bioavailability of the drug in the calf, following single oral administration, is about 80%. The time necessary to obtain the maximum concentration Tmax is 11 hours. The maximum concentration in plasma Cmax is 4 ng/ml. The apparent volume of distribution is 10 l/kg. The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment. Unchanged halofuginone is the major component in the tissues. Highest values have been found in the liver and the kidney. The product is mainly excreted in the urine. The terminal elimination half-life is 11.7 hours after IV administration and 30.84 hours after single oral administration.
PHARMACEUTICAL PARTICULARS
List of excipients
Benzoic acid (E 210)
Tartrazine (E 102)
Lactic acid (E270)
Water for injections
Major incompatibilities
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.